A study of ACER-002 (celiprolol hydrochloride) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS).
Phase of Trial: Phase III
Latest Information Update: 20 May 2016
At a glance
- Drugs Celiprolol (Primary)
- Indications Ehlers-Danlos syndrome
- Focus Therapeutic Use
- 20 May 2016 New trial record
- 10 May 2016 According to an Acer Therapeutics media release, the company plans to file an NDA based on a randomized, controlled clinical study of celiprolol.